Valéry Combes1, Sharissa L Latham2, Beryl Wen2, Anthony C Allison3, Georges E R Grau2. 1. Vascular Immunology Unit, Faculty of Medicine & Bosch Institute, The University of Sydney, Medical Foundation Building, 92-94 Parramatta Road, Camperdown NSW 2006, Australia; School of Life Sciences, The University of Technology, Sydney, Ultimo NSW 2007, Australia. 2. Vascular Immunology Unit, Faculty of Medicine & Bosch Institute, The University of Sydney, Medical Foundation Building, 92-94 Parramatta Road, Camperdown NSW 2006, Australia. 3. Alavita Inc, Palo Alto, California, United States of America.
Abstract
BACKGROUND: Microparticles are now recognised as true biological effectors with a role in immunopathology through their ability to disseminate functional properties. Diannexin, a homodimer of annexin V, binds to PS with a higher affinity and longer blood half-life than the monomer, inhibits prothrombinase complex activity thereby diminishing coagulation and reperfusion injury mediators and prevent microvesicle-mediated material transfer. Our aim was to determine if Diannexin could modulate microparticle production by endothelial cells by interacting with the phosphatidylserine exposure occurring during the release of these vesicles. RESULTS: In this study we showed that fluorescently labelled Diannexin binds to calcimycin-activated endothelial cells but not to resting cells. After overnight incubation, Diannexin enters cells and their released MP carry Diannexin. Some Diannexin seems to be processed via early endosomes and later is found in lysosomes. Both unlabelled Diannexin and fluorescent Diannexin inhibit MP release from TNF-activated endothelial cells. However, Diannexin treatment does not prevent endothelial activation by TNF. In addition, the inhibitory effect of Diannexin on MP release could be observed when cells were pre-, concomitantly or post-treated with cytokines. Scanning electron microscopy showed differences in the numbers and types of protuberances at the cell surface when cells were treated or not with Diannexin. Finally, there is no apparent congruency between fluorescent Diannexin labelling and surface protuberances as shown by correlative microscopy. CONCLUSIONS: Altogether these data suggest that Diannexin can inhibit endothelial vesiculation by binding PS present either at the cell surface or at the level of the inner leaflet of the plasma membrane.
BACKGROUND: Microparticles are now recognised as true biological effectors with a role in immunopathology through their ability to disseminate functional properties. Diannexin, a homodimer of annexin V, binds to PS with a higher affinity and longer blood half-life than the monomer, inhibits prothrombinase complex activity thereby diminishing coagulation and reperfusion injury mediators and prevent microvesicle-mediated material transfer. Our aim was to determine if Diannexin could modulate microparticle production by endothelial cells by interacting with the phosphatidylserine exposure occurring during the release of these vesicles. RESULTS: In this study we showed that fluorescently labelled Diannexin binds to calcimycin-activated endothelial cells but not to resting cells. After overnight incubation, Diannexin enters cells and their released MP carry Diannexin. Some Diannexin seems to be processed via early endosomes and later is found in lysosomes. Both unlabelled Diannexin and fluorescent Diannexin inhibit MP release from TNF-activated endothelial cells. However, Diannexin treatment does not prevent endothelial activation by TNF. In addition, the inhibitory effect of Diannexin on MP release could be observed when cells were pre-, concomitantly or post-treated with cytokines. Scanning electron microscopy showed differences in the numbers and types of protuberances at the cell surface when cells were treated or not with Diannexin. Finally, there is no apparent congruency between fluorescent Diannexin labelling and surface protuberances as shown by correlative microscopy. CONCLUSIONS: Altogether these data suggest that Diannexin can inhibit endothelial vesiculation by binding PS present either at the cell surface or at the level of the inner leaflet of the plasma membrane.
Authors: V Combes; A C Simon; G E Grau; D Arnoux; L Camoin; F Sabatier; M Mutin; M Sanmarco; J Sampol; F Dignat-George Journal: J Clin Invest Date: 1999-07 Impact factor: 14.808
Authors: A Minagar; W Jy; J J Jimenez; W A Sheremata; L M Mauro; W W Mao; L L Horstman; Y S Ahn Journal: Neurology Date: 2001-05-22 Impact factor: 9.910
Authors: Valéry Combes; Fatima El-Assaad; Dorothée Faille; Ronan Jambou; Nicholas H Hunt; Georges E R Grau Journal: Prog Neurobiol Date: 2010-01-29 Impact factor: 11.685
Authors: M Mack; A Kleinschmidt; H Brühl; C Klier; P J Nelson; J Cihak; J Plachý; M Stangassinger; V Erfle; D Schlöndorff Journal: Nat Med Date: 2000-07 Impact factor: 53.440
Authors: Sharissa L Latham; Christine Chaponnier; Vera Dugina; Pierre-Olivier Couraud; Georges E R Grau; Valery Combes Journal: FASEB J Date: 2012-11-16 Impact factor: 5.191
Authors: Narci C Teoh; Hussam Ajamieh; Heng Jian Wong; Kevin Croft; Trevor Mori; Anthony C Allison; Geoffrey C Farrell Journal: PLoS One Date: 2014-09-15 Impact factor: 3.240
Authors: Sigrun Lange; Mark Gallagher; Sharad Kholia; Uchini S Kosgodage; Mariya Hristova; John Hardy; Jameel M Inal Journal: Int J Mol Sci Date: 2017-06-05 Impact factor: 5.923